Abstract
Ethno-phytopharmacology studies the traditional use of plants for the prevention and cure of several diseases. It provides multidisciplinary research on components of medicinal plants, their identification and description, properties, modes of action and interactions with the human organism. Search for new bioactive drugs is another aim of these experimental investigations. Since the World Health Organization (WHO) supports and encourages the introduction of traditional medicine resources into health systems around the world, the use of medicinal plants has shown a marked increase. For this reason, interest in applying scientific methods to validate or refute the traditional use of these plants with the rigors of evidence-based medicine to assess safety, efficacy, and quality has become increasingly important. These three concepts govern the twenty-first century therapy inherent to any conventional drug and allow medicinal plants to aid in the development and advancement of modern medicine, serving as a starting point for the design of new, better, and healthier drugs. In this chapter, parameters to validate medicinal plant attributes such as selection and harvest, extraction and processing methods, analytical techniques to isolate and identify bioactive metabolites, biological activity screening, and other aspects are discussed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Alvino Leite, M. C., de Brito Bezerra, A. P., de Sousa, J. P., & de Oliveira Lima, E. (2015). Investigating the antifungal activity and mechanism(s) of geraniol against Candida albicans strains. Medical Mycology, 53(3), 275–284.
Andersson, J., Forssberg, H., & Zierath, J. (2016). Avermectin and artemisinin – revolutionary therapies against parasitic diseases. Nobelprize.org. https://www.nobelprize.org/nobel_prizes/medicine/laureates/2015/advanced-medicineprize2015.pdf
Arias, T. D. (1999). Glosario de medicamentos: desarrollo, evaluación y uso. Washington, DC: Organización Panamericana de la Salud (OPS). 333 p. ISBN 92 75 32305 4.
Atanasov, A. G., Waltenberger, B., Pferschy-Wenzig, E.-M., Linder, T., Wawrosch, C., Uhrin, P., Temml, V., Wang, L., Schwaiger, S., Heiss, E. H., et al. (2015). Discovery and resupply of pharmacologically active plant-derived natural products: A review. Biotechnology Advances, 33(8), 1582–1614.
Balouiri, M., Sadiki, M., & Ibnsouda, S. K. (2016). Methods for in vitro evaluating antimicrobial activity: A review. Journal of Pharmaceutical Analysis, 6, 71–79.
Brusotti, G., Cesari, I., Dentamaro, A., Caccialanza, G., & Massolini, G. (2014). Isolation and characterization of bioactive compounds from plant resources: The role of analysis in the ethnopharmacological approach. Journal of Pharmaceutical and Biomedical Analysis, 87, 218–228.
Cantón, E., Msrtin, E., & Espinel-ingroff, A. (2007). Métodos estandarizados por el CLSI para el estudio de la sensibilidad a los antifúngicos (documentos M27-A3, M38-A y M44-A). Revista Iberoamericana de Micología, 15, 1. http://www.guia.reviberoammicol.com/Capitulo15.pdf.
Clinical and Laboratory Standards Institute (CLSI). (1999). Methods for determining bactericidal activity of antimicrobial agents (M26-A). Wayne, PA.
Clinical and Laboratory Standards Institute (CLSI). (2017a). Reference method for broth dilution antifungal susceptibility testing of yeasts (M27, 4th ed.). Wayne, PA.
Clinical and Laboratory Standards Institute (CLSI). (2017b). Reference method for broth dilution antifungal susceptibility testing of filamentous Fungi (M38, 3rd ed., p. 62). Wayne, PA.
Clinical and Laboratory Standards Institute (CLSI). (2018). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically (M07, 11th ed.). Wayne, PA.
Clinical and Laboratory Standards Institute (CLSI). (2020). Performance standards for antimicrobial susceptibility testing (M100, 30th ed.). Wayne, PA.
Convention on Biological Diversity. (2011). Nagoya protocol on access to genetic resources and the fair and equitable sharing of benefits arising to the Convention on Biological Diversity. https://www.cbd.int/abs/doc/protocol/nagoya-protocol-en.pdf
Cos, P., Vlietinck, A. J., Vanden, B. D., & Maes, L. (2006). Anti-infective potential of natural products: How to develop a stronger in vitro “proof-of-concept”. Journal of Ethnopharmacology, 106(3), 290–302.
Das, K., Tiwari, R. K. S., & Shrivastava, D. K. (2010). Techniques for evaluation of medicinal plant products as antimicrobial agent: Current methods and future trends. Journal of Medicinal Plants Research, 4(2), 104–111.
Dewanjee, S., Gangopadhyay, M., Bhattacharya, N., Khanra, R., & Dua, T. K. (2015). Bioautography and its scope in the field of natural product chemistry. Journal of Pharmaceutical Analysis, 5(2), 75–84.
EMA. (2006). Committee on Herbal Medicinal Products: Guideline on good agricultural and collection practice for starting materials of herbal origin. London. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-agricultural-collection-practice-gacp-starting-materials-herbal-origin_en.pdf
Espinel-Ingroff, A., Fothergill, A., Peter, J., Rinaldi, M. G., & Walsh, T. J. (2002). Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for. Journal of Clinical Microbiology, 40(9), 3204–3208.
Espinel-Ingroff, A., Aller, A. I., Canton, E., Castañón-Olivares, L. R., Chowdhary, A., Cordoba, S., Cuenca-Estrella, M., Fothergill, A., Fuller, J., Govender, N., et al. (2012). Cryptococcus neoformans-Cryptococcus gattii species complex: An international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. Antimicrobial Agents and Chemotherapy, 56(11), 5898–5906.
Fabricant, D. S., & Farnsworth, N. R. (2001). The value of plants used in traditional medicine for drug discovery. Environmental Health Perspectives, 109(1), 69–75.
Fuentes-Fiallo VR, Lemes Hernández CM, Rodriguez Ferradá CA, & Germosén-Robineau L. (2000). Manual de cultivo y conservacion de plantas medicinales. Tomo II: Cuba (p. 172). ISSN 1028-4796.
Gertsch, J. (2009). How scientific is the science in ethnopharmacology? Historical perspectives and epistemological problems. Journal of Ethnopharmacology, 122(2), 177–183.
Giusiano, G., Rodolfi, M., Mangiaterra, M., Piontelli, E., & Picco, A. M. (2010). Hongos endófitos en 2 plantas medicinales del nordeste argentino. I: Análisis morfotaxonómico de sus comunidades foliares. Boletín Micológico, 25, 15–27.
Hazen, K. C. (1998). Fungicidal versus fungistatic activity of terbinafine and itraconazole: An in vitro comparison. Journal of the American Academy of Dermatology, 38, S37–S41.
Hilbay, R., Chamorro Armas, S., González, M., & Palacios, T. (2016). Reingeniería en los procesos de secado, molienda y tamizado de plantas aromáticas para mejorar la calidad de los derivados, caso: Empresa Jambi Kiwa. FIGEMPA Investig y Desarro, 1(6), 89–99.
Holetz, F. B., Pessini, G. L., Sanches, N. R., Cortez, A. G., Nakamura, C. V., & Dias Filho, B. P. (2002). Screening of some plants used in the Brazilian folk medicine for the treatment of infectious diseases. Memórias do Instituto Oswaldo Cruz, 97(7), 1027–1031.
Kuete, V. (2010). Potential of Cameroonian plants and derived products against microbial infections: A review. Planta Medica, 76(14), 1479–1491.
Kunle, O. F., Egharevba, H. O., & Ahmadu, P. O. (2012). Standardization of herbal medicines – a review. International Journal of Biodiversity and Conservation, 4(3), 101–112.
Malheiros, A., Filho, V. C., Schmitt, C. B., Yunes, R. A., Escalante, A., Svetaz, L., Zacchino, S., & Monache, F. D. (2005). Antifungal activity of drimane sesquiterpenes from Drimys brasiliensis using bioassay-guided fractionation. Journal of Pharmaceutical Sciences, 8(2), 335–339.
Matthews, H., Hanison, J., & Nirmalan, N. (2016). “Omics” -informed drug and biomarker discovery: Opportunities, challenges and future perspectives. Proteomes, 4, 28. https://doi.org/10.3390/proteomes4030028.
Meletiadis, J., Meis, J. F. G. M., Mouton, J. W., & Verweij, P. E. (2002). Methodological issues related to antifungal drug interaction modelling for filamentous fungi. Reviews in Medical Microbiology, 13(3), 101–117.
Meletiadis, J., Antachopoulos, C., Stergiopoulou, T., Pournaras, S., Roilides, E., & Walsh, T. J. (2007). Differential fungicidal activities of amphotericin B and voriconazole against Aspergillus species determined by microbroth methodology. Antimicrobial Agents and Chemotherapy, 51(9), 3329–3337.
Muñoz, F. (1996). Plantas medicinales y aromáticas: estudio, cultivo y procesado (p. 343). Madrid: Mundi-Prensa Libros.
Nazzaro, F., Fratianni, F., Coppola, R., & De Feo, V. (2017). Essential oils and antifungal activity. Pharmaceuticals, 10(4), 1–20.
Ncube, N. S., Afolayan, A. J., & Okoh, A. I. (2008). Assessment techniques of antimicrobial properties of natural compounds of plant origin: Current methods and future trends. African Journal of Biotechnology, 7(12), 1797–1806.
Newman, D. J. (2020). Modern traditional Chinese medicine: Identifying, defining and usage of TCM components. In Advances in pharmacology (Vol. 87, 1st ed., pp. 113–158). Elsevier Inc. https://doi.org/10.1016/bs.apha.2019.07.001
Newman, D. J., & Cragg, G. M. (2020a). Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. Journal of Natural Products, 83(3), 770–803.
Newman, D. J., & Cragg, G. M. (2020b). Plant endophytes and epiphytes: Burgeoning sources of known and “unknown” cytotoxic and antibiotic agents? Planta Medica. Published online ahead of print, 2020 Feb 5, https://doi.org/10.1055/a-1095-1111
Odds, F. C. (2003). Synergy, antagonism, and what the chequerboard puts between them. The Journal of Antimicrobial Chemotherapy, 52(1), 1. https://doi.org/10.1093/jac/dkg301.
Pessini, G. L., Dias Filho, B. P., Nakamura, C. V., & Garcia Cortez, D. A. (2003). Antibacterial activity of extracts and Neolignans from Piper regnellii (Miq.) C. DC. var. pallescens (C. DC.) Yunck. Memórias do Instituto Oswaldo Cruz, 98(8), 1115–1120.
Pfaller, M. A., Sheehan, D. J., & Rex, J. H. (2004). Determination of fungicidal activities against yeasts and molds: Lessons learned from bactericidal testing and the need for standardization. Clinical Microbiology Reviews, 17(2), 268–280.
Rates, S. M. K. (2001). Plants as source of drugs. Toxicon, 39, 603–613.
Rojas, F. D., Sosa, M. D. L. A., Fernández, M. S., Cattana, M. E., Córdoba, S. B., & Giusiano, G. (2014). Antifungal susceptibility of Malassezia furfur, Malassezia sympodialis, and Malassezia globosa to azole drugs and amphotericin B evaluated using a broth microdilution method. Medical Mycology, 52, 641–646.
Salvat, A., Antonnacci, L., Fortunato, R. H., Suarez, E. Y., & Godoy, H. M. (2001). Screening of some plants from Northern Argentina for their antimicrobial activity. Letters in Applied Microbiology, 32(5), 293–297.
Sanches, N. R., Garcia Cortez, D. A., Schiavini, M. S., Nakamura, C. V., & Dias Filho, B. P. (2005). An evaluation of antibacterial activities of Psidium guajava (L.). Brazilian Archives of Biology and Technology, 48(3), 429–436.
Sticher, O. (2008). Natural product isolation. Natural Product Reports, 25, 517–554.
Svetaz, L., Tapia, A., López, S. N., Furlán, R. L. E., Petenatti, E., Pioli, R., Schmeda-Hirschmann, G., & Zacchino, S. A. (2004). Antifungal chalcones and new caffeic acids esters from Zuccagnia punctata acting against soybean infecting fungi. Journal of Agricultural and Food Chemistry, 52(11), 3297–3300.
Tallmadge, E. H. (2018). Patenting natural products after myriad. Harvard Journal of Law & Technology, 30(2), 569–600.
Tanaka, J. C. A., da Silva, C. C., de Oliveira, A. J. B., & Dias Filho, B. P. (2006). Antibacterial activity of indole alkaloids from Aspidosperma ramiflorum. Brazilian Journal of Medical and Biological Research, 39, 387–391.
Van Norman, G. A. (2016). Drugs, devices, and the FDA: Part 1: An overview of approval processes for drugs. JACC Basic to Translational Science, 1(3), 170–179.
WHO. (1992). Convention on biological diversity. https://www.cbd.int/doc/legal/cbd-en.pdf
WHO. (2002). WHO traditional medicine strategy 2002–2005. http://www.beovita.eu/pdf/WHO_EDM_TRM_2004.pdf
WHO. (2003). WHO guidelines on good agricultural and collection practices (GACP) for medicinal plants. https://apps.who.int/medicinedocs/pdf/s4928e/s4928e.pdf
WHO. (2013). WHO traditional medicine strategy 2014–2023 (p. 76). Honk Kong. ISBN 9241506091, 9789241506090.
WHO, IUCN, WWF. (1993). Guidelines on the conservation of medicinal plants (pp 1–38). WHO, IUCN & WWF (Ed.). Gland. ISBN 2-8317-0136-8. https://apps.who.int/medicinedocs/documents/s7150e/s7150e.pdf
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Mussin, J., Giusiano, G. (2020). Ethno–Phytopharmacology: Product Validation Process Based on Traditional Knowledge of Medicinal Plants. In: Chong, P., Newman, D., Steinmacher, D. (eds) Agricultural, Forestry and Bioindustry Biotechnology and Biodiscovery. Springer, Cham. https://doi.org/10.1007/978-3-030-51358-0_17
Download citation
DOI: https://doi.org/10.1007/978-3-030-51358-0_17
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-51357-3
Online ISBN: 978-3-030-51358-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)